Mezigdomide Clinical Trials (2026): 19 Studies for Multiple Myeloma & Recurrent Multiple Myeloma

Where to Participate: All Mezigdomide Trial Sites in the U.S. (52 sites across 16 states)

Every actively recruiting Mezigdomidetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

Mezigdomide clinical trials at a glance: phase × recruitment status

Recruiting Mezigdomide clinical trials (12)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

Mezigdomide clinical trials by indication

Mezigdomide pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Terminated and withdrawn Mezigdomide trials (2)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

• NCT06050512withdrawnMezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
• NCT06163898terminatedA Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

All Mezigdomide trials (19)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

Mezigdomide clinical trials: frequently asked questions

How many Mezigdomide clinical trials are there?

19 Mezigdomide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 11 are actively recruiting participants. 2 are marked completed.

Are Mezigdomide clinical trials recruiting in 2026?

Yes — 11 Mezigdomide trials are actively recruiting in 2026, with 52 U.S. sites across 16 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Mezigdomide being studied for?

Mezigdomide is being studied for Multiple Myeloma, Recurrent Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Refractory Multiple Myeloma and 16 more. The trials are grouped by indication on this page.

What phase is Mezigdomide in?

Mezigdomide clinical trials span 2 Phase 3, 1 Phase 2, 10 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Mezigdomide clinical trials?

The lead sponsor across the most Mezigdomide trials is Celgene, with 11 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Mezigdomideas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed July 17, 2026.